Literature DB >> 6860547

Enhanced Fc receptor expression by a sub-population of murine intra-tumour macrophages following intravenous Corynebacterium parvum therapy.

K Moore, W H McBride.   

Abstract

Intravenous injection of Corynebacterium parvum (C. parvum) 4 days after s.c. inoculation of 5 X 10(5) cells derived from the immunogenic fibrosarcoma FSA/R induced tumour growth inhibition over a period of 21 days in syngeneic C3H/Buf mice. This was not accompanied by a change in the proportions of host cells within the tumour, but the activation state of tumour-infiltrating macrophages was increased following C. parvum therapy. Two macrophage subpopulations were identified in FSA/R tumours after fractionation by unit gravity velocity sedimentation. After i.v. C. parvum therapy the tumour-infiltrating macrophage subpopulation which sedimented between 1 and 6 mm h-1 was consistently activated as determined by measurement of Fc receptor avidity. Other intra-tumour macrophages were generally unaffected by C. parvum treatment. We have previously shown that the host cell fraction sedimenting between 1 and 6 mm h-1 is enriched with monocytes and the data presented in this paper suggest that these cells may enter the tumour in a pre-activated state following intravenous C. parvum therapy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6860547      PMCID: PMC2011359          DOI: 10.1038/bjc.1983.133

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

Review 1.  The functions of the macrophage in malignant disease.

Authors:  P Alexander
Journal:  Annu Rev Med       Date:  1976       Impact factor: 13.739

2.  Evidence for a receptor recognizing antigen complexed immunoglobulin on the surface of activated mouse thymus lymphocytes.

Authors:  T O Yoshida; B Andersson
Journal:  Scand J Immunol       Date:  1972       Impact factor: 3.487

3.  Macrophages in syngeneic animal tumours.

Authors:  R Evans
Journal:  Transplantation       Date:  1972-10       Impact factor: 4.939

4.  Immunologic status of host and response of a methylcholanthrene-induced sarcoma to local x-irradiation.

Authors:  H D Suit; A Kastelan
Journal:  Cancer       Date:  1970-07       Impact factor: 6.860

5.  Separation of cells by velocity sedimentation.

Authors:  R G Miller; R A Phillips
Journal:  J Cell Physiol       Date:  1969-06       Impact factor: 6.384

6.  The macrophage content of some human tumours.

Authors:  C L Gauci; P Alexander
Journal:  Cancer Lett       Date:  1975-09       Impact factor: 8.679

7.  Fc receptor-bearing cells as a reliable marker for quantitation of host lymphoreticular infiltration of progressively growing solid tumors.

Authors:  R S Kerbel; H F Pross
Journal:  Int J Cancer       Date:  1976-10-15       Impact factor: 7.396

8.  Antitumour effect of corynebacterium parvum. Possible mode of action.

Authors:  M Baum; M Breese
Journal:  Br J Cancer       Date:  1976-04       Impact factor: 7.640

9.  Receptors for aggregated IgG on mouse lymphocytes: their presence on thymocytes, thymus-derived, and bone marrow-derived lymphocytes.

Authors:  C L Anderson; H M Grey
Journal:  J Exp Med       Date:  1974-05-01       Impact factor: 14.307

10.  A receptor for antibody on B lymphocytes. I. Method of detection and functional significance.

Authors:  A Basten; J F Miller; J Sprent; J Pye
Journal:  J Exp Med       Date:  1972-03-01       Impact factor: 14.307

View more
  2 in total

1.  Paradoxical presence of T cell anergy during successful T cell-dependent tumour immunotherapy: characterization of a state of T cell 'amnaesia' following systemic administration of C. parvum.

Authors:  W H McBride; S Howie
Journal:  Clin Exp Immunol       Date:  1984-07       Impact factor: 4.330

2.  Propionibacterium acnes Augments Antitumor, Anti-Angiogenesis and Immunomodulatory Effects of Melatonin on Breast Cancer Implanted in Mice.

Authors:  Wamidh H Talib; Suhair Saleh
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.